Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Trevena Inc (NASDAQ: TRVN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Trevena Inc (NASDAQ: TRVN) concerning whether a series of statements by Trevena Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On February 21, 2017, the Company revealed that its painkiller drug, Oliceridine beat a placebo in two Phase 3 trials but slightly underperformed morphine. 

Following the news, NASDAQ: TRVN fell 40% on February 21, 2017.

Based in King of Prussia, Pennsylvania, and founded in 2007 Trevena Inc a biopharmaceutical company, develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions.

If you purchased shares of Trevena Inc (NASDAQ: TRVN) on or before February 21, 2017, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185